Validating a measure of myalgic encephalomyelitis/chronic fatigue syndrome symptomatology.
Brown, Abigail A, Jason, Leonard A · Fatigue : biomedicine, health & behavior · 2014 · DOI
Quick Summary
This study tested whether a questionnaire called the DePaul Symptom Questionnaire (DSQ) accurately measures the symptoms people with ME/CFS experience. Researchers found that ME/CFS symptoms naturally group into three main categories: problems with the nervous system and immune system, problems with thinking and memory, and a worsening of symptoms after physical activity. The questionnaire was shown to be a reliable tool for identifying and measuring these symptom patterns in ME/CFS patients.
Why It Matters
Having a validated, comprehensive symptom measurement tool is essential for both clinical diagnosis and research studies of ME/CFS. This study provides evidence that the DSQ accurately captures the major symptom clusters experienced by patients, which improves how clinicians can assess severity and how researchers can consistently measure treatment outcomes across studies.
Observed Findings
A 3-factor solution emerged from exploratory analysis: Neuroendocrine, Autonomic & Immune Dysfunction; Neurological/Cognitive Dysfunction; and Post-Exertional Malaise
The identified factor structure showed adequate fit when tested on a second, less stringently recruited sample
92.6% of the primary sample met either Fukuda criteria or Canadian Criteria for ME/CFS
Convergent and discriminant validity were established using alternative symptom and functioning measures
Inferred Conclusions
The DSQ is a valid and reliable measure of ME/CFS symptomatology suitable for clinical and research assessment
ME/CFS symptoms naturally cluster into three distinct domains reflecting neuroendocrine/autonomic/immune, neurological/cognitive, and post-exertional components
The identified symptom structure aligns with existing literature on ME/CFS pathophysiology and clinical presentation
The DSQ can differentiate ME/CFS symptomatology from other conditions based on convergent and discriminant validity testing
Remaining Questions
Does the 3-factor structure hold consistently across different demographic groups, geographic regions, and disease severity levels?
How sensitive is the DSQ to longitudinal changes in symptom severity and can it detect treatment-related improvements?
What This Study Does Not Prove
This study does not establish what causes these symptom clusters or prove that the three identified factors represent distinct biological mechanisms. It also does not test whether the DSQ can predict treatment response or disease progression, and the validation was performed on relatively well-characterized samples that may not fully represent all ME/CFS patients globally.
Do the three identified factors correspond to distinct underlying biological or pathophysiological mechanisms, or do they represent overlapping manifestations of a single disease process?
How does the DSQ perform in primary care or non-specialist settings where diagnostic criteria adherence may be less stringent?